Skip to main content
SpringerLink
Log in

Penicillin G/ofloxacin versus erythromycin/amoxicillin-clavulanate in the treatment of severe community-acquired pneumonia

  • Article
  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

Abstract

In a prospective, randomized, multicenter trial, the efficacy of penicillin plus ofloxacin was compared to that of amoxicillin-clavulanate plus erythromycin in the treatment of community-acquired pneumonia. One hundred seventeen hospitalized patients presenting with severe community-acquired pneumonia received either penicillin 3 × 106 U/6 h plus ofloxacin 200 mg twice daily (group A) or amoxicillin-clavulanate 1 g/6 h plus erythromycin 1 g/8 h (group B). Initial assessment included clinical examination, determination of simplified acute physiology score (SAPS), chest X-ray and evaluation of microbiological data obtained from blood, sputum and/or bronchoscopy. Follow-up was documented at 72 h and at 30 days. Both groups were comparable for age, sex, SAPS, chest X-ray, hypoxemia and microbiological data. The causative pathogen was identified in 54 cases (53 %),Streptococcus pneumoniae being most frequent isolate (54.7 %). All organisms cultured were susceptible to at least one of the antibiotics of each combination of the protocol, with the exception of two strains ofPseudomonas aeruginosa. A favorable outcome was observed in 76 % of the patients, equally distributed between the two groups. After completion of therapy there were 12 clinical failures in each group (20.5 %). Six patients in each group (10.3 %) died of infection. Tolerance was similar for both regimens, apart from an increased rate of superficial thrombophlebitis in patients receiving intravenous erythromycin. The combination of penicillin with ofloxacin is as effective and as safe as a previously recommended regimen combining amoxicillin-clavulanate and erythromycin in treating patients with community-acquired pneumonia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fine MJ, Smith DN, Singer DE Hospitalization decision in patients with community-acquired pneumonia: a prospective cohort study. American Journal of Medicine 1990, 89: 713–721.

    Google Scholar 

  2. Ortqvist A Prognosis in community-acquired pneumonia requiring treatment in hospital. Scandinavian Journal of Infectious Diseases 1990, 65, Supplement 1: 62–69.

    Google Scholar 

  3. Venkatesen P, Mac Farlane JT Epidemiology, pathogenesis and presention of pneumonia. Current Opinions in Infectious Diseases 1991, 4: 145–149.

    Google Scholar 

  4. Fang GD, Fine M, Orloff J, Arisumi D, Yu VL, Kapoor W, Grayston JT, Wang SP, Kohler R, Muder RR New and emerging etiologies for community-acquired pneumonia with implications for therapy: a prospective multicenter study of 359 cases. Medicine 1990, 69: 307–316.

    Google Scholar 

  5. Vankatesen P, Gladman J, Mac Farlane JT, Barker D, Berman P, Kinnear W, Finch RG A hospital study of community-acquired pneumonia in the elderly. Thorax 1990, 45: 254–258.

    Google Scholar 

  6. Karalus NC, Cursons RT, Leng RA, Mahood CB, Rothwell RPG, Habcock B, Cepulis S, Wawatai M, Coleman L Community-acquired pneumonia: aetiology and prognostic index evaluation. Thorax 1991, 46: 413–418.

    Google Scholar 

  7. Feldman C, Kallenbach JM, Levy H, Reinach SG, Hurwitz MD, Thoburn JR, Koornhof HJ Community-acquired pneumonia of diverse etiology: prognostic features in patients admitted to an intensive care unit and a “severity of illness score.” Intensive Care Medicine 1989, 15: 302–307.

    Google Scholar 

  8. Woodhead MA, Mac Farlane JT, McCracken JS, Rose D, Finch RG Prospective study of the aetiology and outcome of pneumonia in the community. Lancet 1987, i: 671–674.

    Google Scholar 

  9. Marrie TJ, Durant H, Yates L Community-acquired pneumonia requiring hospitalization. Reviews of Infectious Diseases 1989, 11: 586–599.

    Google Scholar 

  10. Jacobs MR, Koornhof HJ, Robins-Browne RM, Stevenson CM, Vermaak ZA, Freiman I, Miller GB, Witcomb M, Issaacson M, Ward JI, Austrian R Emergence of multiply resistant pneumococci. New England Journal of Medicine 1978, 299: 735–740.

    Google Scholar 

  11. Feldman C, Kallenbach KJM, Miller SD, Thornburn JR, Koornhof HJ Community-acquired pneumonia due to penicillin-resistant pneumococci. New England Journal of Medicine 1985, 313: 615–617.

    Google Scholar 

  12. Geslin P, Fremaux A, Sissia G Epidémiologie de la résistance deStreptococcus pneumoniae aux β-lactamines en France et dans le monde. In: Caulin C, Chastang C (ed): Infections à pneumocoques de sensibilité diminuée aux β-lactamines. Springer Verlag, Paris, 1993, p. 55–71.

    Google Scholar 

  13. Lipsky BA, Tack NJ, Chou Kuo, San-Pin Wang, Grayston JT Ofloxacin treatment ofChlamydia pneumoniae lower respiratory tract infection. American Journal of Medicine 1990, 89: 722–724.

    Google Scholar 

  14. Lephonte P, Rouquet RM, Didier A, Lemozy J Identification des pneumopathies infectieuses bactériennes. Limites du Laboratoire. Stratégie antibiotique empirique. Médecine et Maladies Infectieuses 1986, 6: 418–424.

    Google Scholar 

  15. Lévy M, Dromer F, Brion N, Leturdu F, Carbon C Community-acquired pneumonia: importance of initial noninvasive bacteriologic and radiographic investigations. Chest 1988, 92: 43–48.

    Google Scholar 

  16. Ortqvist A, Hedlund J, Grillner L, Jalonen E, Kallings I, Leinonen M, Kallin M Aetiology, outcome and prognostic factors in community-acquired pneumonia requiring hospitalization. European Respiratory Journal 1990, 3: 1105–1113.

    Google Scholar 

  17. Le Gall JR, Loirat P, Alperovitch A, Glaser P, Granthill C, Mathieu D A simplified acute physiology score for ICU patients. Critical Care Medicine 1984, 12: 975–977.

    Google Scholar 

  18. Pallares R, Gudiol F, Linares J, Ariza J, Rufi G, Murgui L, Dorca J, Viladrich PF Risk factors and response to antibiotic therapy in adults with bacteremic pneumonia caused by penicillin-resistant pneumococci. New England Journal of Medicine 1987, 317: 18–22.

    Google Scholar 

  19. Klugman KP Pneumococcal resistance to antibiotics. Clinical Microbiology Reviews 1990, 3: 171–196.

    Google Scholar 

  20. Pachon J, Prados MD, Capote F, Cuello JA, Garchano J, Verano A Severe community-acquired pneumonia: etiology, prognosis and treatment. American Review of Respiratory Disease 1990, 142: 369–373.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Département de Microbiologie Clinique, Centre Hospitalier, 1 rue du Tresum, 74011, Annecy Cedex, France

    J. Gaillat, J. P. Bru & A. Sedallian

Authors
  1. J. Gaillat
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. P. Bru
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Sedallian
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gaillat, J., Bru, J.P. & Sedallian, A. Penicillin G/ofloxacin versus erythromycin/amoxicillin-clavulanate in the treatment of severe community-acquired pneumonia. Eur. J. Clin. Microbiol. Infect. Dis. 13, 639–644 (1994). https://doi.org/10.1007/BF01973989

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01973989

Keywords

Search

Navigation